PHOENIX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled “Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells” (U.S. Application No. 17/931,868).
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20close-up%20shot%20of%20a%20Broadcom%20chip%20by%20g0d4ather%20via%20Adobe%20Stock.jpeg)
/A%20close-up%20of%20a%20SpaceX%20sign%20by%20Sundry%20Photography%20via%20Adobe%20Stock.jpeg)
/NVIDIA%20Corp%20video%20chip-by%20Antonio%20Bordunovi%20via%20iStock.jpg)